This is why some of the FDA’s advisors are worried about this pill:
“‘I think the potential for this drug to drive some very challenging variants into the public is a major, major concern,’ said James E.K. Hildreth, president of Meharry Medical College.”
https://t.co/ndTS1SCUHN https://t.co/yxaKx7fjXt
— Vince Coglianese (@VinceCoglianese)
Dec 3, 2021
from http://twitter.com/VinceCoglianese
via IFTTT